Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

This region encodes for the reverse transcriptase and protease enzymes, the targets of current antiretroviral drugs. Specific gene sequences are compared with that of a reference (wild-type ...

Drug regimens now offer more potent, less toxic and more durable choices in the treatment of HIV disease than ever before. This has led to a need to consider the convenient, sequential use of ...

Anemia prevalence was high in adult patients with HIV infection on HAART, with female sex, older age, and nonsuppressed viral load status identified as significant predictors.

The 40th annual AIDS Walk Los Angeles will take place Sunday in a very different world than when it first started.

Anti-retroviral Drugs Market size will reach USD 42.5 billion by 2032. Growing awareness and early diagnosis of HIV will accelerate industry expansion over 2024–2032 by promoting timely ...

Jefferies analyst Akash Tewari has assigned their bullish stance on ARVN stock, giving a Buy rating yesterday. Akash Tewari’s rating is ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Retail pharmacies to garner more attention The anti-retroviral drugs market from retail pharmacy segment will amass notable gains by 2032 due to easy accessibility and convenience for patients ...

In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...